RESEARCH PAPER
Year : 2021  |  Volume : 12  |  Issue : 2  |  Page : 61-67

Therapeutic drug monitoring of imatinib in patients of chronic myeloid leukemia – Chronic phase


1 Department of Clinical hematology, Medical Division, Command Hospital Air Force, Bengaluru, Karnataka, India
2 Department of Biochemistry, Armed Forces Medical College, Pune, Maharashtra, India
3 Department of Obstetrics and Gynaecology, Command Hospital Air Force, Bengaluru, Karnataka, India
4 Department of Endocrinology, Medical Divison Command hospital Air Force, Bengaluru, Karnataka, India
5 Department of Nephrology, Medical Divison Command hospital Air Force, Bengaluru, Karnataka, India

Correspondence Address:
Vijoy Kumar Jha
Command Hospital Air Force, Bengaluru - 560 007, Karnataka
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jpp.jpp_28_21

Rights and Permissions

Introduction: Tyrosine kinase inhibitor is recommended for the initial management of chronic phase chronic myeloid leukemia (CP CML) based on the more favorable balance of toxicity and long-term disease control. Background: Mean trough plasma Imatinib Mesylate (IM) levels are detected to be significantly higher in patients with a complete cytogenetic response or major molecular response (MMR). Methodology: The primary objective of the study was to correlate the IM drug levels with MMR on two different occasions at least 3 months apart and to study the variation in the plasma trough levels of IM during the treatment with standard dose for at least 12 months. Results: After exclusion, 30 patients of CML-CP in MMR, on standard dose over a period of 2 years were finally analyzed. The mean IM plasma levels (IPLs) of the first sample for all patients were 1722 ± 566 ng/ml (IPL-1) with a corresponding mean molecular response (MR) 0.0257 ± 0.0279 breakpoint cluster region-abelson murine leukemia (BCR-ABL) IS % (MR-1). The mean IPLs of the second sample for all patients were 1549 ± 375 ng/ml (IPL-2) with a corresponding mean MR 0.0143 ± 0.0184 BCR-ABL IS % (MR-2). Area under the receiver operating characteristic curve for IPL-1 was 0.565 and IPL-2 was 0.639. For IM level at second point of 1800 ng/ml, the specificity for predicting MMR was 81.8% and sensitivity was 31.6%. Conclusion: Monitoring of trough IM plasma concentrations may become the part of standard management of CML patients.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed220    
    Printed8    
    Emailed0    
    PDF Downloaded29    
    Comments [Add]    

Recommend this journal